In vitro activity of cefpirome and vancomycin in combination against gentamicin- susceptible and gentamicin-resistant Staphylococcus aureus A. Carricajo, R. Vermesch, G. Auhert Clinical Microbiology and Infection Volume 7, Issue 4, Pages 218-220 (April 2001) DOI: 10.1046/j.1198-743x.2001.00238.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
Figure 1 Time kill curves: (a) vancomycin (VAN) alone, cefpirome (CPO) alone and vancomycin plus cefpirome for the homogeneous GR-MRSA; (b) vancomycin alone, cefpirome alone and vancomycin plus cefpirome for the heterogeneous GR-MRSA; (c) vancomycin alone, cefpirome alone and vancomycin plus cefpirome for the heterogeneous GS-MRSA. Clinical Microbiology and Infection 2001 7, 218-220DOI: (10.1046/j.1198-743x.2001.00238.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions